Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2005 2
2006 2
2008 3
2009 1
2010 4
2011 5
2012 2
2013 4
2014 9
2015 12
2016 7
2017 5
2018 5
2019 11
2020 13
2021 14
2022 18
2023 24
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 20Nazri, 20bin, 20Muhayiddin
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) …
METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but l …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free article. Clinical Trial.
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 to less than 90 mL/min per 1.73 m(2) with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. ...
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 to les …
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Percentage change in first morning void UACR from baseline to the end of treatment at week 14 was -3% (95% CI -19 to 17) with placebo, -22% (-36 to -7) with BI 690517 3 mg, -39% (-50 to -26) with BI 690517 10 mg, and -37% (-49 to -22) with BI 690517 20 mg monotherapy. BI 6 …
Percentage change in first morning void UACR from baseline to the end of treatment at week 14 was -3% (95% CI -19 to 17) with placebo, -22% …
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.
METHODS: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR …
METHODS: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Ital …
The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness.
Dennis M, Sandercock P, Graham C, Forbes J; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration; Smith J. Dennis M, et al. Health Technol Assess. 2015 Sep;19(76):1-90. doi: 10.3310/hta19760. Health Technol Assess. 2015. PMID: 26418530 Free PMC article. Clinical Trial.
Secondary outcomes in IPC compared with no-IPC participants were death in the treatment period in 156 (10.8%) versus 189 (13.1%) (p = 0.058); skin breaks in 44 (3.1%) versus 20 (1.4%) (p = 0.002); and falls with injury in 33 (2.3%) versus 24 (1.7%) (p = 0.221). ...
Secondary outcomes in IPC compared with no-IPC participants were death in the treatment period in 156 (10.8%) versus 189 (13.1%) (p = 0.058) …
Correction: Probiotic and prebiotic supplementation ameliorates chronic restraint stress-induced male reproductive dysfunction.
Akram M, Azmal Ali S, Kaul G. Akram M, et al. Food Funct. 2023 Oct 16;14(20):9470. doi: 10.1039/d3fo90086j. Food Funct. 2023. PMID: 37796026
Correction for 'Probiotic and prebiotic supplementation ameliorates chronic restraint stress-induced male reproductive dysfunction' by Mohd Akram et al., Food Funct., 2023, 14, 8558-8574, https://doi.org/10.1039/D3FO03153E....
Correction for 'Probiotic and prebiotic supplementation ameliorates chronic restraint stress-induced male reproductive dysfunction' by Mo …
Overcoming Therapeutic Inertia as the Achilles' Heel for Improving Suboptimal Diabetes Care: An Integrative Review.
Chew BH, Mohd-Yusof BN, Lai PSM, Khunti K. Chew BH, et al. Endocrinol Metab (Seoul). 2023 Feb;38(1):34-42. doi: 10.3803/EnM.2022.1649. Epub 2023 Feb 16. Endocrinol Metab (Seoul). 2023. PMID: 36792353 Free PMC article. Review.
The known causes of TI include factors at the level of the physician (50%), patient (30%), and health system (20%). Although TI is often multifactorial, the literature suggests that 28% of strategies are targeted at multiple levels of causes, 38% at the patient level, 26% …
The known causes of TI include factors at the level of the physician (50%), patient (30%), and health system (20%). Although TI is of …
Potential mechanisms of hepatitis B virus induced liver injury.
Suhail M, Abdel-Hafiz H, Ali A, Fatima K, Damanhouri GA, Azhar E, Chaudhary AG, Qadri I. Suhail M, et al. World J Gastroenterol. 2014 Sep 21;20(35):12462-72. doi: 10.3748/wjg.v20.i35.12462. World J Gastroenterol. 2014. PMID: 25253946 Free PMC article. Review.
Low glycaemic index or low glycaemic load diets for people with overweight or obesity.
Chekima K, Yan SW, Lee SWH, Wong TZ, Noor MI, Ooi YB, Metzendorf MI, Lai NM. Chekima K, et al. Cochrane Database Syst Rev. 2023 Jun 22;6(6):CD005105. doi: 10.1002/14651858.CD005105.pub3. Cochrane Database Syst Rev. 2023. PMID: 37345841 Review.
For the secondary outcomes, low GI/GL diets may result in little to no difference in fat mass compared to higher GI/GL diets (MD -0.86 kg, 95% CI -1.52 to -0.20; I(2) = 6%; 6 studies, 295 participants; low certainty-evidence). ...
For the secondary outcomes, low GI/GL diets may result in little to no difference in fat mass compared to higher GI/GL diets (MD -0.86 kg, 9 …
137 results